Get the Stockscreener App
9.81
7.01%
-0.74
Scisparc Ltd stock is traded at $9.81, with a volume of 822.11K.
It is down -7.01% in the last 24 hours and up +8.64% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$10.55
Open:
$10
24h Volume:
822.11K
Relative Volume:
0.90
Market Cap:
$5.62M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0424
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
+129.74%
1M Performance:
+8.64%
6M Performance:
-50.45%
1Y Performance:
+257.44%
1-Day Range:
$8.24
$10.11
1-Week Range:
$4.28
$15.65
52-Week Range:
$2.61
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
9.81 | 6.05M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Subsidiary Wins Conditional TSXV Nod for CliniQuantum Acquisition, Amends Deal Terms - TipRanks
SciSparc (Nasdaq: SPRC) unit to buy 54% of CliniQuantum in share deal - Stock Titan
SciSparc stock surges 200% on NeuroThera acquisition progress - Investing.com
Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest - RTTNews
SciSparc stock surges 157% after subsidiary gets conditional TSX approval for major acquisition - Pluang
Why is SciSparc stock skyrocketing on Thursday? - MSN
SciSparc Ltd. (SPRC) Stock Explodes 202% Following NeuroThera’s TSX Exchange Milestone - MEXC
SciSparc Ltd. (SPRC) Stock: Shares Soar 202% on NeuroThera’s TSX Approval - MEXC
SciSparc jumps 150.8% as subsidiary wins conditional exchange approval for CliniQuantum deal - Quiver Quantitative
Why Is SciSparc Stock Skyrocketing On Thursday? - Benzinga
SciSparc Ltd. (SPRC) Stock Explodes 202% Following NeuroThera's TSX Exchange Milestone - Blockonomi
SciSparc (SPRC) Stock Rockets 202% as NeuroThera Gets TSX Green Light - MoneyCheck
NeuroThera receives conditional approval for CliniQuantum deal - Investing.com UK
SciSparc’s NeuroThera Labs Gets Conditional Approval to Acquire CliniQuantum - geneonline.com
SciSparc stock surges 200% on NeuroThera acquisition progress By Investing.com - Investing.com Canada
Trending Stocks Today | SciSparc Shoots up 219.58% - Moomoo
SPRC Stock Explodes As Bullish Upgrades Hit Tape - StocksToTrade
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum - markets.businessinsider.com
NeuroThera receives conditional approval for CliniQuantum deal By Investing.com - Investing.com Nigeria
SPRC Stock Draws Bullish Upgrades As Traders Circle - timothysykes.com
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition ... - Caledonian Record
Neurothera Labs Inc. Provides Update On Proposed Acquisition Of Majority Stake In Cliniquantum Ltd. - TradingView
SciSparc Ltd. (SPRC) Gains 2.07% in Light Trading – Key Support Holds Above $4.00Price Target - thelegaladvocate.com
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - MSN
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Neurothera Labs Announces Adoption of Semi-Annual Reporting - TheNewswire
SPRC Technical Analysis | Trend, Signals & Chart Patterns | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
SciSparc | SCHEDULE 13G/A: Others - Moomoo
L.I.A. Pure Capital files 13G/A reporting - Stock Titan
Number of shareholders of SciSparc Ltd. – NASDAQ:SPRC - TradingView
TradingKey - TradingKey
SciSparc receives Nasdaq conditional compliance notice on listing requirements By Investing.com - Investing.com Australia
SciSparc receives Nasdaq conditional compliance notice on listing requirements - Investing.com
SciSparc Regains Conditional Nasdaq Compliance After Equity Shortfall - TipRanks
SciSparc (NASDAQ: SPRC) regains Nasdaq compliance but faces future test - Stock Titan
SPRC - Finviz
Neurothera Labs Announces Continuance into Ontario - TheNewswire
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
SciSparc (NASDAQ: SPRC) 20-F shows widening losses and going concern risk - Stock Titan
SciSparc stock rallies after AutoMax files motion on pending merger - MSN
Neurothera Labs Engages bullVestor for Investor Relations Activities - TheNewswire
SciSparc receives Nasdaq notice over stockholders’ equity shortfall - MSN
SPRC Stock Pops On Volatile Run As Traders Circle - timothysykes.com
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):